Skip to main content
Clinical Trials/ISRCTN11565460
ISRCTN11565460
Completed
Phase 2

Interreg diabetes centre for personalised medicine - unscheduled care in diabetes - study 2: inpatient study

niversity of the Highlands and Islands0 sites60 target enrollmentNovember 10, 2021

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of the Highlands and Islands
Enrollment
60
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

2021 Results article in https://doi.org/10.1111/dme.14753 (added 10/05/2022)

Registry
who.int
Start Date
November 10, 2021
End Date
January 31, 2022
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of the Highlands and Islands

Eligibility Criteria

Inclusion Criteria

  • Phase 2, Part B: pilot study – use of Flash Glucose Monitoring:
  • 1\. Adults (aged 18 years and older)
  • 2\. Diagnosed with diabetes
  • 3\. Admitted to hospital wards defined in phase 1
  • 4\. Able to read and understand the participant information sheet (PIS)
  • 5\. Able to give written informed consent
  • Phase 2, Part C: pilot study \- evaluation interviews:
  • 1\. Patients or HCPs that have participated in phase 2, part B
  • 2\. Able to read and understand the participant information sheet (PIS)
  • 3\. Able to give written informed consent

Exclusion Criteria

  • Phase 2, Part B: pilot study \- use of flash glucose monitoring:
  • 1\. Children or young people (aged younger than 18 years)
  • 2\. Not diagnosed with diabetes
  • 3\. Admitted to hospital wards not defined in phase 1
  • 4\. Pregnancy or gestational diabetes
  • 5\. Significant intercurrent illness and/or terminal diagnosis
  • 6\. Have a condition and/or treatment known to affect variability of blood glucose, such as on kidney dialysis
  • 7\. Already using a Flash Glucose Monitoring or continuous monitoring device
  • 8\. Unable to read and understand the participant information sheet (PIS)
  • 9\. Unable to give written informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials